West Pharmaceutical Services (WST) Payables (2009 - 2026)

West Pharmaceutical Services has disclosed Payables across 18 years of filings, most recently posting $252.3 million for Q1 2026.

• Payables for Q1 2026 came in at $252.3 million, up 10.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $252.3 million (up 10.46% YoY), and the FY2025 annual result was $253.7 million, up 6.02% from the prior year.
• Payables came in at $252.3 million for Q1 2026 at West Pharmaceutical Services, down from $253.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $255.8 million in Q3 2025 to a low of $188.9 million in Q3 2022.
• The 5-year median for Payables is $233.8 million (2023), against an average of $231.2 million.
• Peak annual rise in Payables reached 21.49% in 2022, while the deepest fall reached 9.05% in 2022.
• West Pharmaceutical Services' Payables stood at $215.4 million in 2022, then advanced by 12.53% to $242.4 million in 2023, then dropped by 1.28% to $239.3 million in 2024, then rose by 6.02% to $253.7 million in 2025, then declined by 0.55% to $252.3 million in 2026.
• The last three Payables figures came in at $252.3 million (Q1 2026), $253.7 million (Q4 2025), and $255.8 million (Q3 2025), per Business Quant data.